美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Loxo Oncology

234.66

0.0000

成交量：- -

成交額：- -

市值：72.17億

市盈率：-112.40

高：234.66

開：234.66

低：234.66

收：234.66

52周最高：234.93

52周最低：103.50

股本：3,075.46萬

流通股本：2,752.00萬

量比：- -

換手率：- -

股息：- -

股息率：- -

每股收益(TTM):-2.0877

每股收益(LYR):-5.3102

淨資產收益率：--

總資產收益率：--

市淨率：19.03

市盈率(LYR):-44.19

資料載入中...

總覽公司新聞資訊公告

公司資料

公司名字：

Loxo Oncology

交易所：

NASDAQ

成立時間：

- -

員工人數：

- -

公司地址：

- -

官網：

http://www.loxooncology.com

郵編：

- -

電話：

- -

傳真：

- -

簡介：

Loxo Oncology, Inc.於2013年5月9號在特拉華州成立。公司開發有針對性的基因定義的患者群體的治療癌症的小分子療法。公司的開發方式轉換了相關癌症轉換成藥物，這些藥物能夠有效的和高選擇性的達到關鍵科學見解的預期目標。這些藥物通常能夠達到更高的目標任務和改善相關腫瘤的反應。公司識別和優先考慮的目標有兩種方式。首先，該公司使用的臨床試驗數據來評估藥物的發展，響應信號和識別那些承諾也證明藥物的具體限制，如吸收差，差的分佈或有害的副作用。第二，該公司評估學術研究發現新的目標與新興的驗證。一旦確定目標,公司使用先進的第三方技術來開發候選產品旨在增強目標接觸和特異性。

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/LOXO/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LOXO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LOXO\",,,,,undefined,":{"symbol":"LOXO","market":"US","secType":"STK","nameCN":"Loxo Oncology","latestPrice":234.66,"timestamp":1557432000000,"preClose":234.66,"halted":3,"volume":0,"delay":0,"changeRate":0,"floatShares":27520039,"shares":30754634,"eps":-2.087713,"marketStatus":"停牌","change":0,"latestTime":"05-09 16:00:00 EDT","open":234.66,"high":234.66,"low":234.66,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.087713,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1774252800000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1406865600000,"exchange":"NASDAQ","adjPreClose":234.66,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LOXO\",,,,,undefined,":{"symbol":"LOXO","floatShares":27520039,"roa":"--","roe":"--","lyrEps":-5.31023,"shares":30754634,"dividePrice":0,"high":234.66,"amplitude":0,"preClose":234.66,"low":234.66,"week52Low":103.5,"pbRate":"19.03","week52High":234.93,"institutionHeld":0,"latestPrice":234.66,"eps":-2.087713,"divideRate":0,"volume":0,"delay":0,"ttmEps":-2.087713,"open":234.66,"prevYearClose":234.66},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LOXO\",params:#limit:5,,,undefined,":[{"market":"US","date":"2018-11-08","symbol":"LOXO","fiscalQuarterEnding":"2018/09","expectedEps":-0.07,"name":null,"time":"盤前","type":"earning","dateTimestamp":1541653200000,"reportTimeType":"pre","actualEps":-2.26},{"market":"US","date":"2018-08-09","symbol":"LOXO","fiscalQuarterEnding":"2018/06","expectedEps":-0.54,"name":null,"time":"盤前","type":"earning","dateTimestamp":1533787200000,"reportTimeType":"pre","actualEps":-0.39},{"market":"US","date":"2018-05-08","symbol":"LOXO","fiscalQuarterEnding":"2018/03","expectedEps":-0.6,"name":null,"time":"盤前","type":"earning","dateTimestamp":1525752000000,"reportTimeType":"pre","actualEps":-0.12},{"market":"US","date":"2018-03-01","symbol":"LOXO","fiscalQuarterEnding":"2017/12","expectedEps":-1.22,"name":null,"time":"盤前","type":"earning","dateTimestamp":1519880400000,"reportTimeType":"pre","actualEps":-0.69},{"market":"US","date":"2017-11-02","symbol":"LOXO","fiscalQuarterEnding":"2017/09","expectedEps":-1.38,"name":null,"time":"盤前","type":"earning","dateTimestamp":1509595200000,"reportTimeType":"pre","actualEps":-1.12}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LOXO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LOXO\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.loxooncology.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":-0.0207},{"period":"1month","weight":-0.055},{"period":"3month","weight":-0.047},{"period":"6month","weight":-0.0228},{"period":"1year","weight":0.1469},{"period":"ytd","weight":-0.0489}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"Loxo Oncology, Inc.於2013年5月9號在特拉華州成立。公司開發有針對性的基因定義的患者群體的治療癌症的小分子療法。公司的開發方式轉換了相關癌症轉換成藥物，這些藥物能夠有效的和高選擇性的達到關鍵科學見解的預期目標。這些藥物通常能夠達到更高的目標任務和改善相關腫瘤的反應。 公司識別和優先考慮的目標有兩種方式。首先，該公司使用的臨床試驗數據來評估藥物的發展，響應信號和識別那些承諾也證明藥物的具體限制，如吸收差，差的分佈或有害的副作用。第二，該公司評估學術研究發現新的目標與新興的驗證。一旦確定目標,公司使用先進的第三方技術來開發候選產品旨在增強目標接觸和特異性。","exchange":"NASDAQ","name":"Loxo Oncology","nameEN":"Loxo Oncology"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"LOXO\",market:\"US\",,,undefined,":null}}